Read by QxMD icon Read

Expert Review of Pharmacoeconomics & Outcomes Research

Tomasz Bochenek, Ewa Kocot, Marcin Rodzinka, Brian Godman, Katarzyna Maciejewska, Susan Kamal, Andrzej Pilc
BACKGROUND: The appropriate access to public information is very important for healthcare system stakeholders. OBJECTIVE: The goal of this study was to examine how the execution of the formally existing right to public information on the HTA-based recommendations on reimbursement of new health technologies from public funds has been changing in Poland. METHODS: All recommendations published within two predefined equal periods of time between 2013 and 2015 were analyzed...
November 24, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Jacopo Giuliani, Andrea Remo, Andrea Bonetti
To examine the magnitude of the clinical benefit from first-line tyrosine kinase inhibitors (TKIs) advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR)-mutations. Areas covered: The present evaluation was restricted to pivotal phase III RCTs in first-line for advanced NSCLC with activating EGFR-mutations. We have subsequently applied the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) to the above pivotal phase III RCTs, to derive a relative ranking of the magnitude of clinically meaningful benefit...
November 21, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Jamie Caro
No abstract text is available yet for this article.
November 10, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Simon B Zeichner, Christine G Kohn, Daniel A Goldstein
Introduction Despite its FDA approval and incorporation into the National Comprehensive Cancer Network (NCCN) treatment guidelines, ramucirumab (RAM) is associated with a drug acquisition cost that is substantially higher than other approved options. Given its substantial cost, the presence of a viable alternative treatment option, and its minimal survival improvement, the usefulness of RAM in clinical practice has been called into question. Areas covered In this paper, we outline the cost, benefits, and economic implications of RAM from a US perspective, as it is used in the treatment of mCRC...
November 9, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Amos Massele, Johanita Burger, Francis Kalemeera, Mary Jande, Thatayaone Didimalang, Aubrey Chichonyi Kalungia, Kidwell Matshotyana, Michael Law, Brighid Malone, Olayinka Ogunleye, Margaret Oluka, Bene D Paramadhas, Godfrey Rwegerera, Sekesai Zinyowera, Brian Godman
The second Medicines Utilization Research in Africa (MURIA) group workshop and symposium again brought researchers together from across Africa to improve their knowledge of drug utilization (DU) methodologies and exchange ideas to further progress DU research in Africa. This built on extensive activities from the first conference including workshops and multiple publications. Anti-infectives were again the principal theme for the 2016 symposium following the workshops. This included presentations regarding strategies to improve antibiotic utilization among African countries, such as point-prevalence studies, as well as potential ways to reduce self-purchasing of antibiotics...
November 3, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Ghislaine A P G van Mastrigt, Mickaël Hiligsmann, Jacobus J C Arts, Pieter H Broos, Jos Kleijnen, Silvia M A A Evers, Marian H J M Majoie
Systematic reviews of economic evaluations are useful for synthesizing economic evidence about health interventions and for informing evidence-based decisions. Areas covered: As there is no detailed description of the methods for performing a systematic review of economic evidence, this paper aims to provide an overview of state-of-the-art methodology. This is laid out in a 5-step approach, as follows: step 1) initiating a systematic review; step 2) identifying (full) economic evaluations; step 3) data extraction, risk of bias and transferability assessment; step 4) reporting results; step 5) discussion and interpretation of findings...
November 2, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
F W Thielen, Gapg Van Mastrigt, L T Burgers, W M Bramer, Hjm Majoie, Smaa Evers, J Kleijnen
This article is part of the series "How to prepare a systematic review of economic evaluations (EES) for informing evidence-based healthcare decisions", in which a five-step approach is proposed. Areas covered: This paper focuses on the selection of relevant databases and developing a search strategy for detecting EEs, as well as on how to perform the search and how to extract relevant data from retrieved records. Expert commentary: Thus far, little has been published on how to conduct systematic review EEs...
November 2, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Bfm Wijnen, Gapg van Mastrigt, W K Redekop, Hjm Majoie, Rja de Kinderen, Smaa Evers
This article is part of the series "How to Prepare a Systematic Review (SR) of Economic Evaluations (EE) for Informing Evidence-based Healthcare Decisions" in which a five-step-approach for conducting a SR of EE is proposed. Areas covered: This paper explains the data extraction process, the risk of bias assessment and the transferability of EEs by means of a narrative review and expert opinion. SRs play a critical role in determining the comparative cost-effectiveness of healthcare interventions. It is important to determine the risk of bias and the transferability of an EE...
October 20, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Mingyue Zhao, Jing Wu
OBJECTIVE: Examine the effects of regulated competition on the drug pricing in China. METHODS: Based on product-level data, a regression method was employed for pricing by using data from Tianjin Urban Employee Basic Medical Insurance (UEBMI) database. The market competition measures distinguished generic competition within the same molecule from therapeutic competition within the same therapeutic class. RESULTS: The increases in pricing are inversely related to the number of generic competitions...
October 20, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Anne-Laure Mouterde, François Bocquet, Isabelle Fusier, Pascal Paubel
No abstract text is available yet for this article.
October 12, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Mark Jm van Duin, Rafael Conde, Ben Wijnen, Silva Maa Evers, Javier L Gonzalez-Rodriguez, Mark Jg Govers, Mickaël Hiligsmann
OBJECTIVE: To assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia. METHODS: A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogotá to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs. RESULTS: Of all patients, 72% experienced CMs; of these, half experienced ≥2 CMs (N=49)...
October 12, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Her Hsin Tsai, Christopher Black
Introduction Vedolizumab is a novel humanised monoclonal IgG1 antibody gut selective anti-integrin specifically targeting α4β7 integrins in the gut and found to be efficacious in the treatment of ulcerative colitis. Areas covered Research investigating the cost-effectiveness of vedolizumab is limited. This review considers data from the manufacturers, the evidence research group commissioned by NICE to conduct a single technology appraisal, and the decision of NICE itself to appraise what is currently known about the cost-effectiveness of vedolizumab for moderately to severely active ulcerative from a UK perspective...
October 11, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Sabine Vogler, Nina Zimmermann, Zaheer-Ud-Din Babar
BACKGROUND: In recent years, high-cost medicines have increasingly been challenging the public health budget in all countries including high-income economies. In this context, this study aims to survey, analyze and compare prices of medicines that likely contribute to high expenditure for the public payers in high-income countries. METHODS: We chose the following 16 European countries: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, the Netherlands, Portugal, Sweden, Slovakia, Spain and United Kingdom...
October 11, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Linda Henry, Zobair Younossi
We used published literature from 2013- 2016, to review data regarding the new all oral interferon and ribavirin free direct acting antiviral (DAA's) treatment regimens. Areas covered: Specifically, this paper will address DAA's clinical efficacy, their associated patient reported outcomes, their adherence to treatment, and their cost-effectiveness of treatment using studies from the United States. Expert commentary: The current data suggest that cure and elimination of HCV appears to be on the horizon; however, more research is needed to verify similar results from real world practices...
October 6, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Carl Rudolf Blankart, Ricarda Milstein, Meike Rybczynski, Helke Schüler, Yskert von Kodolitsch
Marfan syndrome is a rare multisystem disease of the connective tissue, which affects multiple organ systems. advances in healthcare have doubled the life-expectancy of patients over the past three decades. to date, there is no comprehensive review that consolidates economic considerations and care for marfan patients. Areas covered: Present research suggests that there may be a link between treatment pattern, disease progression and economic costs of Marfan syndrome. It indicates that an early detection of the disease and preventive interventions achieve a dual aim...
October 6, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Sun Hee Rim, Gery P Guy, K Robin Yabroff, Kathleen A McGraw, Donatus U Ekwueme
This systematic review examines the excess cost of chronic conditions on the economic burden of cancer survivorship among adults in the US. Areas covered: Twelve published studies were identified. Although studies varied substantially in populations, comorbidities examined, methods, and types of cost reported, costs for cancer survivors with comorbidities generally increased with greater numbers of comorbidities or an increase in comorbidity index score. Survivors with comorbidities incurred significantly more in total medical costs, out-of-pocket costs, and costs by service type compared to cancer survivors without additional comorbidities...
October 6, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Raphaela Marie Louisa Dierks, Olivier Bruyère, Jean-Yves Reginster, Florent-Frederic Richy
Technological innovations, new regulations, increasing costs of drug productions and new demands are only few key drivers of a projected alternation in the pharmaceutical industry. The purpose of this review is to understand the macro economic factors responsible for the business model revolution to possess a competitive advantage over market players. Areas covered: Existing literature on macro-economic factors changing the pharmaceutical landscape has been reviewed to present a clear image of the current market environment...
October 4, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Erkki Soini, Taru Hallinen, Mélanie Brignone, Rosanne Campbell, Françoise Diamand, Sandrine Cure, Maria Aalto-Setälä, Natalya Danchenko, Hannu J Koponen, Katarzyna Kolasa
OBJECTIVES: To assess the cost-utility of vortioxetine versus relevant comparators (agomelatine, bupropion SR, sertraline, and venlafaxine XR) in the Finnish setting in major depressive disorder (MDD) patients with inadequate response to selective serotonin- /serotonin-norepinephrine reuptake inhibitors. METHODS: A one-year analysis was conducted using a decision tree with a Markov state transition component. The health states were remission, relapse and recovery...
September 29, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Mondher Toumi, Ekkehard Beck, Steve Sherman, Leyla Mohseninejad, Samuel Aballéa
No abstract text is available yet for this article.
December 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Adam L Gordois, Peter P Toth, Ruben Gw Quek, Emma M Proudfoot, Carly J Paoli, Shravanthi R Gandra
People with cardiovascular disease (CVD) often require time off work to recover from illness or surgery; for example, following a myocardial infarction (MI) or stroke. These individuals incur income losses, work-related productivity is reduced for employers, and output is reduced for the wider economy. Productivity impacts to the economy also arise due to CVD-related mortality. Areas covered: A systematic literature review was conducted to identify and collate studies that report the magnitude of work-related productivity losses associated with CVD generally or specific cardiovascular (CV) events or conditions (coronary heart disease, MI, stroke, transient ischemic attack, angina, heart failure, peripheral artery disease, coronary revascularization)...
December 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"